# Teva Pharmaceutical Industries (TEVA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TEVA
## Company Profile
- Ticker: TEVA
- Exchange: NYSE
- Sector: Biopharma
- Location: Israel and listed in the U
- Tags: Oncology, CNS
## Stock Data
- Close: 41.25 USD
- Market cap: 38519244233.759995 USD
- Last updated: 2026-10-13
## Business Overview
### Global Branded and Generic Medicines Company
Teva Pharmaceutical Industries is a global pharmaceutical company with businesses in innovative medicines, generic drugs, biosimilars, and active pharmaceutical ingredients. Its commercial reach spans North America, Europe, and international markets, supported by large-scale manufacturing and regulatory capabilities.
### Core Innovative Brands
Teva's principal innovative growth brands are AUSTEDO for movement disorders, AJOVY for migraine prevention, and UZEDY, a long-acting risperidone formulation for schizophrenia. These products are shifting the company's portfolio toward specialty medicines with differentiated clinical profiles and longer commercial duration.
### Neuroscience Pipeline
The neuroscience pipeline includes ecopipam for pediatric Tourette syndrome and a long-acting injectable formulation of olanzapine for schizophrenia. Together with UZEDY, these programs are intended to establish a broader franchise spanning movement disorders and long-acting psychiatric treatments.
### Immunology Development
Teva is developing duvakitug, an anti-TL1A antibody partnered with Sanofi, in ulcerative colitis, Crohn's disease, and additional inflammatory disorders. TEV-408, an anti-IL-15 antibody designed for infrequent subcutaneous dosing, is being advanced in vitiligo.
### Generics and Biosimilars Platform
Generic medicines remain a large part of Teva's business and provide global scale across dosage forms and therapeutic areas. The company is expanding its biosimilar portfolio through internal programs and partnerships, including products in ophthalmology, immunology, and neurology.
## Why The Stock Is Moving

The latest monitored headline was “Teva to Host R&D Day on Wednesday, November 11 in New York City”. TEVA was little changed in the corresponding trading session, closing at $41.25 on Oct 13, 2026.

## Future Catalysts

- Potential U.S. launch of olanzapine long-acting injectable in the fourth quarter of 2026, subject to regulatory approval.
- Initiation of a Phase 2 study of TEV-408 in vitiligo in the fourth quarter of 2026.
- FDA review of the submitted NDA for ecopipam in pediatric Tourette syndrome.

## Recent News
- 2026-10-12 21:45 EST — [Teva to Host R&D Day on Wednesday, November 11 in New York City](https://biopharmsignal.com/news/TEVA/teva-to-host-r-d-day-on-wednesday-november-11-in-new-york-city-a699e8c7) — Source: Teva Pharmaceutical Industries
- 2026-10-09 11:00 EST — [Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia](https://biopharmsignal.com/news/TEVA/teva-announces-u-s-food-and-drug-administration-fda-approval-of-weltruza-olanzap-9904ddc1) — Source: Teva Pharmaceutical Industries
- 2026-10-02 12:00 EST — [Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome](https://biopharmsignal.com/news/TEVA/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-trea-b199e324) — Source: Teva Pharmaceutical Industries
- 2026-10-02 12:00 EST — [Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients](https://biopharmsignal.com/news/TEVA/journal-of-child-neurology-publishes-review-highlighting-dopamine-s-role-in-tour-74c002b6) — Source: Teva Pharmaceutical Industries
- 2026-09-30 20:32 EST — [TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness](https://biopharmsignal.com/news/TEVA/tapi-technology-api-services-names-serge-rogasik-ceo-to-lead-next-chapter-of-gro-0e515be3) — Source: Teva Pharmaceutical Industries